A. Sinclair Dunlop
Pharmaceutics, clinical sciences
Mr. Dunlop has over twenty years of experience successfully delivering competitive returns to international investors. Prior to co-founding Epidarex Capital, Mr. Dunlop raised and managed MASA Life Science Ventures, LP (“MLSV” ). MLSV’s investors include several leading institutions and corporations in Japan and Korea, including a ‘top-ten’ Japanese Pharmaceutical company, the largest distributor of cardiac-health medical devices in Japan, a global financial institution and one of Japan’s leading publicly-traded Biotechnology companies. Mr. Dunlop’s international network of blue-chip co-investors, his experienced management team and a Scientific Advisory Board of renowned experts successfully built and managed a portfolio of leading life science and health technology companies. He currently serves on the Board of Directors of Apellis Pharmaceuticals Inc., Clyde Biosciences Ltd., EM Imaging Ltd., Mironid Ltd., and Sirakoss Ltd. He holds an M.B.A. from Columbia Business School, an M.A. (Honours) in Political Economy from the University of Glasgow and a M.A. in International Relations from Syracuse University.
Pharmaceutics, clinical sciences,biotechnology, biomedical, drug delivery, Health Sciences, Sustainability, testing and inspection , chemical, environmental solutions, biochemistry